Savitz DA. Invited commentary: interpreting associations between exposure biomarkers and pregnancy outcome. Am J Epidemiol. 2014;179(5):545-547.
Kadhel P, Monfort C, Costet N, et al. Chlordecone exposure, length of gestation, and risk of preterm birth. Am J Epidemiol. 2014;179(5):536-544.
Guzelian PS. Comparative toxicology of chlordecone (kepone) in humans and experimental animals. Annu Rev Pharmacol Toxicol. 1982;22(1):89-113.
Cohn WJ, Boylan JJ, Blanke RV, et al. Treatment of chlordecone (kepone) toxicity with cholestyramine. Results of a controlled clinical trial. N Engl J Med. 1978;298(5): 243-248.
Soine PJ, Blanke RV, Guzelian PS, et al. Preferential binding of chlordecone to the protein and high density lipoprotein fractions of plasma from humans and other species. J Toxicol Environ Health. 1982;9(1): 107-118.
Wolff MS, Anderson HA, Britton JA, et al. Pharmacokinetic variability and modern epidemiology-the example of dichlorodiphenyltrichloroethane, body mass index, and birth cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(10): 1925-1930.
Salas SP, Marshall G, Gutiérrez BL, et al. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension. 2006;47(2): 203-208.
